Xeris Biopharma (NSDQ:XERS) announced today that it entered into a collaboration agreement with Merck (NYSE:MRK) for its XeriJect technology.
Chicago-based Xeris’ collaboration with Merck includes an option to license the XeriJect suspension-based formulation technology for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations.
Get the full story at our sister site, Drug Delivery Business News.
Xeris Pharmaceuticals (NSDQ:XERS) announced today that the FDA approved its supplemental new drug application for the Gvoke kit.
Chicago-based Xeris’ Gvoke (Ogluo in Europe) a ready-to-use pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia for people with diabetes ages 2 and above.
Get the full story at our sister site, Drug Delivery Business News.
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it achieved a milestone for the payor coverage of its Gvoke glucagon injection.
Approximately 91% of Medicare patients, 88% of commercially insured patients and a growing number of Medicaid lives have unrestricted access to Gvoke, Xeris said in a news release.
Get the full story at our sister site, Drug Delivery Business News.
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo.
Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia in adults, adolescents and children two years of age and older with diabetes mellitus.
Get the full story at our sister site, Drug Delivery Business News.
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it priced a registered direct offering of common stock at $27 million.
Chicago-based Xeris is offering nearly 6.6 million shares of common stock to funds managed by Deerfield Management Company, which are existing investors in the company, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Xeris Pharmaceuticals today said it has launched its Gvoke HypoPen glucagon injection to treat severe hypoglycemia.
The autoinjector is designed to treat severe hypoglycemia in adults and children with diabetes that are ages two years and older. The premixed autoinjector has no visible needle and has a reliable delivery method. According to the company, 99% of people were able to use the device correctly and 99% of adults and 100% of kids had their blood sugars raised to safe levels.
Get the full story on our sister site, Drug Delivery Business News.
Xeris Pharmaceuticals today said it has launched its Gvoke HypoPen glucagon injection to treat severe hypoglycemia.
The autoinjector is designed to treat severe hypoglycemia in adults and children with diabetes that are ages two years and older. The premixed autoinjector has no visible needle and has a reliable delivery method. According to the company, 99% of people were able to use the device correctly and 99% of adults and 100% of kids had their blood sugars raised to safe levels.
It is available in 0.5mg/0.1mL doses for children who weigh less than 100 pounds and 1mg/0.2mL for adolescents and adults who weigh more than 100 pounds.
“We are excited to announce that Gvoke HypoPen is now available. The simplicity and reliability of Gvoke HypoPen has the potential to change people’s ability to confidently respond to a severe hypoglycemic event in a timely manner,” CEO Paul Edick said in a news release. “In addition, as we prepared for launch, we had…